REGENXBIO Inc. $RGNX Shares Acquired by PDT Partners LLC

Key Points

• PDT Partners LLC increased its stake in REGENXBIO Inc. by 62.7% during the first quarter, acquiring 39,501 additional shares, and now owns approximately 0.20% of the company valued at $733,000.
• Several hedge funds have also increased their investments in REGENXBIO, highlighting strong institutional interest, as they collectively own 88.08% of the company's stock.
• REGENXBIO reported a loss of $1.38 EPS for the last quarter, missing estimates, with revenue of $21.36 million compared to expectations of $40.87 million.

PDT Partners LLC lifted its holdings in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 62.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 102,516 shares of the biotechnology company's stock after acquiring an additional 39,501 shares during the period. PDT Partners LLC owned 0.20% of REGENXBIO worth $733,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Janney Montgomery Scott LLC purchased a new position in shares of REGENXBIO during the first quarter worth approximately $484,000. Wealth Enhancement Advisory Services LLC purchased a new position in shares of REGENXBIO during the first quarter worth approximately $123,000. Price T Rowe Associates Inc. MD grew its position in shares of REGENXBIO by 9.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 23,910 shares of the biotechnology company's stock worth $185,000 after acquiring an additional 1,982 shares during the last quarter. BNP Paribas Financial Markets grew its position in shares of REGENXBIO by 370.1% during the fourth quarter. BNP Paribas Financial Markets now owns 96,093 shares of the biotechnology company's stock worth $743,000 after acquiring an additional 75,652 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new position in REGENXBIO in the 4th quarter valued at $568,000. 88.08% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms recently weighed in on RGNX. Wall Street Zen lowered shares of REGENXBIO from a "hold" rating to a "strong sell" rating in a research report on Saturday, August 9th. HC Wainwright reiterated a "buy" rating and issued a $34.00 price objective on shares of REGENXBIO in a research report on Tuesday, August 19th. Chardan Capital reiterated a "buy" rating and issued a $52.00 price objective on shares of REGENXBIO in a research report on Friday, August 8th. Royal Bank Of Canada lowered their price objective on shares of REGENXBIO from $21.00 to $17.00 and set an "outperform" rating on the stock in a research report on Friday, August 8th. Finally, Barclays lowered their price objective on shares of REGENXBIO from $50.00 to $37.00 and set an "overweight" rating on the stock in a research report on Friday, August 8th. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat.com, REGENXBIO currently has an average rating of "Moderate Buy" and a consensus price target of $28.38.

REGENXBIO Price Performance

Shares of NASDAQ RGNX traded up $0.29 during trading on Friday, hitting $9.71. 609,824 shares of the company were exchanged, compared to its average volume of 643,702. The company has a market cap of $490.45 million, a price-to-earnings ratio of -2.82 and a beta of 1.17. REGENXBIO Inc. has a 1 year low of $5.03 and a 1 year high of $13.48. The firm's fifty day moving average price is $8.65 and its 200 day moving average price is $8.18.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its earnings results on Thursday, August 7th. The biotechnology company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($1.13) by ($0.25). The company had revenue of $21.36 million for the quarter, compared to analysts' expectations of $40.87 million. REGENXBIO had a negative return on equity of 66.95% and a negative net margin of 112.70%. On average, research analysts forecast that REGENXBIO Inc. will post -4.84 earnings per share for the current year.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.